收费全文 | 24731篇 |
免费 | 3095篇 |
国内免费 | 636篇 |
耳鼻咽喉 | 182篇 |
儿科学 | 403篇 |
妇产科学 | 390篇 |
基础医学 | 1649篇 |
口腔科学 | 1248篇 |
临床医学 | 5486篇 |
内科学 | 3355篇 |
皮肤病学 | 324篇 |
神经病学 | 1265篇 |
特种医学 | 296篇 |
外国民族医学 | 1篇 |
外科学 | 2401篇 |
综合类 | 2362篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 2433篇 |
眼科学 | 303篇 |
药学 | 2625篇 |
16篇 | |
中国医学 | 2188篇 |
肿瘤学 | 1529篇 |
2024年 | 50篇 |
2023年 | 975篇 |
2022年 | 1127篇 |
2021年 | 1933篇 |
2020年 | 2004篇 |
2019年 | 1651篇 |
2018年 | 1452篇 |
2017年 | 1268篇 |
2016年 | 1310篇 |
2015年 | 1103篇 |
2014年 | 2098篇 |
2013年 | 2151篇 |
2012年 | 1476篇 |
2011年 | 1620篇 |
2010年 | 1236篇 |
2009年 | 1070篇 |
2008年 | 1098篇 |
2007年 | 929篇 |
2006年 | 843篇 |
2005年 | 685篇 |
2004年 | 506篇 |
2003年 | 454篇 |
2002年 | 283篇 |
2001年 | 254篇 |
2000年 | 164篇 |
1999年 | 109篇 |
1998年 | 75篇 |
1997年 | 72篇 |
1996年 | 73篇 |
1995年 | 62篇 |
1994年 | 51篇 |
1993年 | 34篇 |
1992年 | 26篇 |
1991年 | 31篇 |
1990年 | 14篇 |
1989年 | 29篇 |
1988年 | 29篇 |
1987年 | 12篇 |
1986年 | 15篇 |
1985年 | 16篇 |
1984年 | 10篇 |
1983年 | 19篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 8篇 |
1975年 | 8篇 |
Objective
This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.Study Design
Taking the example of new direct-acting antivirals against hepatitis C virus, the paper asks whether and how the cost-effectiveness (CE) opinions issued by the French National Health Authority improve the information available to support the pricing decisions.Methods
The analysis compares the assessment of these drugs based on three different sources: CE opinions, clinical opinions, and the published cost-utility analyses (CUA) available in the literature and identified through a systematic review.Results
The results show that CE opinions bring to the fore three issues prone to impact the incremental cost utility ratio and those were not available to the decision maker through clinical opinions or published CUA: the stage of treatment initiation, the modeling of the disease progression, and the uncertainty around the efficacy rates.Conclusions
France has introduced the criterion of the cost per QALY gained in the pricing and regulation of innovative pharmaceuticals since 2013. Our analysis shows that the use of CUA does enhance the information available to the decision makers on the value of the treatments. 相似文献Objective
It is useful for reviewers of economic evaluations to assess quality in a manner that is consistent and comprehensive. Checklists can allow this, but there are concerns about their reliability and how they are used in practice. We aimed to describe how checklists have been used in systematic reviews of health economic evaluations.Methods
Meta-review with snowball sampling. We compiled a list of checklists for health economic evaluations and searched for the checklists’ use in systematic reviews from January 2010 to February 2018. We extracted data regarding checklists used, stated checklist function, subject area, number of reviewers, and issues expressed about checklists.Results
We found 346 systematic reviews since 2010 that used checklists to assess economic evaluations. The most common checklist in use was developed in 1996 by Drummond and Jefferson, and the most common stated use of a checklist was quality assessment. Checklists and their use varied within subject areas; 223 reviews had more than one reviewer who used the checklist.Conclusions
Use of checklists is inconsistent. Eighteen individual checklists have been used since 2010, many of which have been used in ways different from those originally intended, often without justification. Different systematic reviews in the same subject areas would benefit from using one checklist exclusively, using checklists as intended, and having 2 reviewers complete the checklist. This would increase the likelihood that results are transparent and comparable over time. 相似文献Aims: To critically review, summarise, and discuss the implementation literature in the field of aphasiology to date, in order to guide clinical aphasiologists to work towards closing the evidence-practice gaps in aphasia management.
Main contribution: A review of the literature in this developing area of expertise in the field of aphasiology, with examples of practical applications.
Conclusions: Only six implementation studies have been published in aphasia (related to conversation partner training, discourse analysis, information provision, and collaborative goal-setting practices), showing there is a need for capacity building in this area. Therefore, we are not yet able to state what interventions are effective in which context, nor fully understand how behaviour change occurs for clinicians providing aphasia management. Implications for speech-language pathologists are discussed. An overarching call to action is the need for clinicians and researchers to work together to drive future implementation efforts that can succeed in closing the aphasia management evidence-practice gaps. 相似文献